Haemonetics Buys Ireland-based Vivasure to Expand Vascular Closure Portfolio

Boston, MA, January 9, 2026 (PRNewswire) -- Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, a Galway-based medtech company developing next-generation percutaneous vessel closure technology. Vivasure’s PerQseal® Elite system uses a fully bioabsorbable, suture-free patch to close large-bore access sites and has already secured CE Mark approval in Europe, with a U.S. FDA PMA submission completed in 2025. The deal includes €100 million in upfront cash (approximately €52 million net of prior investments and loans) plus up to €85 million in contingent payments tied to sales growth and milestones, funded through Haemonetics’ existing cash reserves.

Read full article here.